Stocks and Investing Stocks and Investing
Tue, February 28, 2023

Tazeen Ahmad Maintained (SRPT) at Strong Buy and Held Target at $160 on, Feb 28th, 2023


Published on 2024-10-28 01:58:40 - WOPRAI, Tazeen Ahmad
  Print publication without navigation


Tazeen Ahmad of B of A Securities, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy and Held Target at $160 on, Feb 28th, 2023.

Tazeen has made no other calls on SRPT in the last 4 months.



There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 1 agrees with Tazeen's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Judah Frommer of "Credit Suisse" Maintained at Hold with Increased Target to $137 on, Wednesday, February 15th, 2023


These are the ratings of the 6 analyists that currently disagree with Tazeen


  • Joseph Schwartz of "SVB Leerink" Reiterated at Buy and Held Target at $160 on, Friday, January 20th, 2023
  • Gil Blum of "Needham" Maintained at Strong Buy with Increased Target to $160 on, Tuesday, January 10th, 2023
  • Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $160 on, Thursday, December 22nd, 2022
  • Colin Bristow of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $158 on, Friday, December 16th, 2022
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $190 on, Thursday, November 3rd, 2022
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $171 on, Thursday, November 3rd, 2022
Contributing Sources